Primary Care Physician, Luis Vives Health Center, Alcala de Henares, Madrid, Spain.
Primary Care Physician, Henares Azuqueca Health Center, Guadalajara, Spain.
Curr Allergy Asthma Rep. 2022 Nov;22(11):151-161. doi: 10.1007/s11882-022-01041-2. Epub 2022 Sep 10.
Asthma and chronic obstructive pulmonary disease (COPD) are chronic respiratory diseases that remain uncontrolled in many patients, despite the wide range of therapeutic options available. This review analyzes the available clinical evidence on 3 budesonide/formoterol DPI devices, Spiromax, Turbuhaler, and Easyhaler, in terms of patient-reported outcomes (PROs), inhaler errors, and asthma and COPD control.
The effectiveness of dry powder inhalers (DPI) depends largely on the device and the patient's inhaler technique. Equally important are the patient's perception of the inhaler and adherence. Given the high burden of these diseases, it is important that efforts be made to select the best DPI for each patient and to analyze the impact of these variables to help improve the health and quality of life of our patients. This review provides a comprehensive overview of the present knowledge about PROs, inhaler handling errors, and asthma and COPD control achieved by Spiromax, Turbuhaler, and Easyhaler.
尽管有多种治疗选择，但哮喘和慢性阻塞性肺疾病（COPD）仍然是许多患者无法控制的慢性呼吸道疾病。本综述分析了现有关于布地奈德/福莫特罗三种干粉吸入器（DPI），即 Spiromax、Turbuhaler 和 Easyhaler 的临床证据，内容涉及患者报告的结局（PRO）、吸入器错误以及哮喘和 COPD 的控制情况。
干粉吸入器（DPI）的有效性在很大程度上取决于设备和患者的吸入器技术。同样重要的是患者对吸入器的感知和依从性。鉴于这些疾病的负担很重，重要的是要努力为每个患者选择最佳的 DPI，并分析这些变量的影响，以帮助改善我们患者的健康和生活质量。本综述全面概述了 Spiromax、Turbuhaler 和 Easyhaler 在患者报告的结局、吸入器操作错误以及哮喘和 COPD 控制方面的现有知识。
